Fujitsu
Not logged in » Login
X

Please login

Please log in with your Fujitsu Partner Account.

Login


» Forgot password

Register now

If you do not have a Fujitsu Partner Account, please register for a new account.

» Register now

Recent Discussion:

NickBown | 22.12.2018, 14:18
We have come across this issue as well, and don't seem to have found a way around it (the server is ...
NickBown | 20.12.2018, 18:40
Hi everyoneWe've got an RX2540 M1 which won't boot past the Fujitsu splash screen (which shows the i...
MarkM | 15.10.2018, 11:33
Hi there.I do not believe the Fujitsu policy on this subject has changed.So NO you can not order dri...
Oct 30 2019

Fujitsu Launches Japan's First System for Automatically Generating Electronic Submission Data for Pharmaceuticals

tsClinical for SDTM Automation contributes to new drug development in Japan by supporting and promoting the use of electronic data application

Fujitsu Limited announced today that it has developed tsClinical for SDTM Automation, a solution for pharmaceutical companies that automatically converts electronic study data to the standardized Study Data Tabulation Model (SDTM) format.

SDTM Automation is available for pharmaceutical companies in Japan as of today. This solution can automatically convert the submission data to the standard SDTM format that pharmaceutical companies must submit to regulatory agencies when applying for approval of a new drug, which is promoted by the Clinical Data Interchange Standards Consortium (CDISC), an organization that establishes global standards for clinical study data.

By automatically converting the submission data, this solution prevents issues caused by human error or misunderstanding of the standard in manual conversion, reducing the cost required to convert electronic study data to SDTM format and improving the quality of the data. The Pharmaceuticals and Medical Devices Agency (PMDA), a regulatory agency in Japan, will require all applications to be submitted electronically in SDTM format starting in April 2020.

By offering this solution, Fujitsu is providing world-leading support for the automatic generation of SDTM data (patent pending). This will quickly resolve issues that many pharmaceutical companies may face, such as ensuring the quality of SDTM data, securing human resources to generate the data, and minimizing data generation costs, while also supporting PMDA in their efforts to promote the use of clinical data, contributing to new drug development in Japan.

The major features of this solution are:

  • Improved application data quality and shorter submission preparation times through unified management of conversion specification documents;
  • Reduced labor and SDTM data generation costs through automation;
  • Support for a wide range of data formats from different types of data collection systems, including EDC systems.

 

To lear more, please visit Fujitsu’s press release.

Nuno Costa

 

About the Author:

Nuno Costa

Channel Business Development Associate

SHARE

Comments on this article

No comments yet.

Please Login to leave a comment.